News
![Netgem Trading Summary : Over 30% growth of the subscriber base in 2021. Targeting over 500,000 subscribers by the end of 2022 (+ 40%).](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Netgem Trading Summary : Over 30% growth of the subscriber base in 2021. Targeting over 500,000 subscribers by the end of 2022 (+ 40%).
Paris, January 25, 2022,
The total number of subscribers[1] to the Group's services reached 363,000 at the end of December 2021, up more than 30% over the year. Over the period gross profit grew by
![Madvertise - 2022 FINANCIAL CALENDAR](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Madvertise - 2022 FINANCIAL CALENDAR
Press Release Paris, January 21, 2022 – 6 PM
2022 FINANCIAL CALENDAR
Madvertise (Euronext Growth - FR0010812230 - ALMNG), the French AdTech company specializing in mobile centric digital
![PRISMAFLEX INTERNATIONAL : Growth prospects confirmed in Q3: +24% on a like-for-like basis - Strong Printing activity](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
PRISMAFLEX INTERNATIONAL : Growth prospects confirmed in Q3: +24% on a like-for-like basis - Strong Printing activity
Significant points:
- Printing activity in Q3 attained its highest level on record to stand at €9.2 million (+37%) and confirms its growth dynamic.
- Hardware activity, slightly down over the
![BD MULTIMEDIA : Acquisition of METACOLLECTOR](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
BD MULTIMEDIA : Acquisition of METACOLLECTOR
BD MULTIMEDIA announces the closing of an agreement to acquire METACOLLECTOR.
METACOLLECTOR is a platform for bringing public domain heritage art into the world of NFT.
METACOLLECTOR will soon
![THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE
Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
![DOLFINES (EX DIETSWELL) : DOLFINES pre-qualified by Saudi Aramco](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
DOLFINES (EX DIETSWELL) : DOLFINES pre-qualified by Saudi Aramco
Press Release – January 4, 2022
DOLFINES pre-qualified by Saudi Aramco for future tenders on inspection and Acceptance services contracts for its drilling rigs
After being audited by Saudi Aramco
![THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022
Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
![GECI INTERNATIONAL : 2021-22 FIRST-HALF EARNINGS](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
GECI INTERNATIONAL : 2021-22 FIRST-HALF EARNINGS
2021-22 FIRST-HALF EARNINGS: Improvement in current operating income and financial structure further strengthened
During the Board meeting on December 16, 2021, the Directors reviewed and approved
![FERMENTALG : NextStage AM acquires a stake in Fermentalg alongside Theodore H. Nixon and issues free share subscription warrants](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
FERMENTALG : NextStage AM acquires a stake in Fermentalg alongside Theodore H. Nixon and issues free share subscription warrants
Libourne – 16 December 2021 – Fermentalg (Euronext – FALG), a major French player in microalgae, has announced an equity investment from the NextStage AM investment fund in connection with the
![PRISMAFLEX INTERNATIONAL : 2021-2022 half-year results: Upturn in activity and return to profits](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
PRISMAFLEX INTERNATIONAL : 2021-2022 half-year results: Upturn in activity and return to profits
2021-2022 six-month period analysis
- Activity up 26% driven by a strong upturn in Printing activity (+51% for the period), despite the on-going health crisis, notably in Q1.
- EBITDA positive at
![GROUPE LDLC : OL GROUPE AND THE LDLC GROUP PRESENT THE LDLC ARENA](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
GROUPE LDLC : OL GROUPE AND THE LDLC GROUP PRESENT THE LDLC ARENA
As part of the indoor arena project at OL Valley, OL Groupe and the LDLC Group are delighted to announce a naming agreement for OL Groupe's soon-to-be-built events arena in Décines. It will be
![GROUPE LDLC : FIRST HALF 2021/2022 EARNINGS UP SHARPLY](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
GROUPE LDLC : FIRST HALF 2021/2022 EARNINGS UP SHARPLY
- FIRST HALF CONSOLIDATED REVENUES OF €333.5M, UP 6%
- GROSS MARGIN RATE UP 1.2 PP TO 23.1%
- EBITDA UP 20% TO €30.7M - EBITDA MARGIN OF 9.2%
- 2021/2022 INTERIM DIVIDEND OF €0.80
Olivier de la
![METabolic EXplorer announces the second process resulting from its ALTANØØVTM platform for the production of L-Valine.](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
METabolic EXplorer announces the second process resulting from its ALTANØØVTM platform for the production of L-Valine.
METabolic EXplorer announces the second process resulting from its ALTANØØVTM platform for the production of L-Valine
- Patented technology
- Fermentation process validated at the pre-pilot stage
![DOLFINES (EX DIETSWELL) : DOLFINES is actively pursuing the adaptation of its organization](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
DOLFINES (EX DIETSWELL) : DOLFINES is actively pursuing the adaptation of its organization
Press Release – November 30, 2021
DOLFINES is actively pursuing the adaptation of its organization to meet the requirements of the energy transition market
- Legal separation of conventional and
![Median Technologies Announces New Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd3BRSFE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6f39fecf5146be08cb4f343c975d6fff3d55bd8d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Median_strapline.jpg?locale=us)
Median Technologies Announces New Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules. New
![GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBqRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32e5498581c41f5af17897302b60481289223182/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo+Centre+Hospitalier+XV-XX.jpg?locale=us)
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
![MADVERTISE ENTERS INTO EXCLUSIVE DISCUSSIONS WITH A VIEW TO ACQUIRING A STAKE IN VECTAURY](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
MADVERTISE ENTERS INTO EXCLUSIVE DISCUSSIONS WITH A VIEW TO ACQUIRING A STAKE IN VECTAURY
Press Release
Paris, 18 November 2021 – 6 pm
MADVERTISE ENTERS INTO EXCLUSIVE DISCUSSIONS
WITH A VIEW TO ACQUIRING A STAKE IN VECTAURY
Madvertise (Euronext Growth - FR0010812230 - ALMNG), the French
![GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBqRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32e5498581c41f5af17897302b60481289223182/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo+Centre+Hospitalier+XV-XX.jpg?locale=us)
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative
![GECI INTERNATIONAL : 2021-22 FIRST-HALF REVENUES](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
GECI INTERNATIONAL : 2021-22 FIRST-HALF REVENUES
GECI International, the Digital and Technology specialist, is reporting stable first-half revenues, in line with its target to return to profitability.
FIRST-HALF KEY DEVELOPMENTS
The Group's
![Valbiotis meldet auf der Jahrestagung der American Heart Association (AHA) positive präklinische Ergebnisse für TOTUM•070 gegen Hypercholesterinämie](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Valbiotis meldet auf der Jahrestagung der American Heart Association (AHA) positive präklinische Ergebnisse für TOTUM•070 gegen Hypercholesterinämie
Valbiotis (Paris: ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und
![Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211114005021/en/
TOTUM•070 preclinical results AHA 2021 (Graphic
![GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBqRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32e5498581c41f5af17897302b60481289223182/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo+Centre+Hospitalier+XV-XX.jpg?locale=us)
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
![Sensorion to present in person at “Jefferies London Healthcare Conference” : https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0dxVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--df3db62501cd2dac51e6a4832a420790d1de65b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-sensorion2.jpg?locale=us)
Sensorion to present in person at “Jefferies London Healthcare Conference”
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
![DOLFINES (EX DIETSWELL) : 2021 1st half results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
DOLFINES (EX DIETSWELL) : 2021 1st half results
Press Release – October 29, 2021
2021 1st HALF RESULTS
DOLFINES, an independent specialist in engineering and services for the renewable and conventional energy industry, announces its results for
![PRISMAFLEX INTERNATIONAL : Anticipated upturn in activity confirmed for S1 2021-2022 - Total sales: EUR 23.2 million (+26%)](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
PRISMAFLEX INTERNATIONAL : Anticipated upturn in activity confirmed for S1 2021-2022 - Total sales: EUR 23.2 million (+26%)
Significant points:
- Strong upturn in S1 Print activity (+51%), taking it above pre-crisis levels with Q2 sales up 2% on Q2 2019-2020.
- Growth of traditional Hardware activity; S1 LED display